Catalyst

Slingshot members are tracking this event:

Advaxis (ADXS) Announces Phase 2 GOG-0265 Results Evaluating Lead Candidate Axalimogene Filolisbac in Patients with Persistent/Recurrent Metastatic Carcinoma of the Cervix

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ADXS

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 24, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2, Gog-0265, Lead Candidate, Axalimogene Filolisbac, Filolisbac, Persistent, Recurrent Ethmoid Sinus Obstruction, Metastatic Carcinoma Of The Cervix